A medulloblastoma is the most common malignant brain tumor in children. The treatment of this tumor consists of the surgical (partial) removal of the tumor, followed by radiotherapy and chemotherapy. Unfortunately, this treatment is associated with very harmful (permanent) side effects as a result of severe brain damage. There is an urgent need for a new therapy on the one hand for children for whom the current treatments have failed and on the other hand due to the harmful consequences of the current treatments.
Placental growth factor
Peter Carmeliet has studied the placental growth factor PIGF for several years now. PIGF plays a critical role in the growth of blood vessels in a tumor. PIFG enables blood vessels to grow towards the tumor cells to supply the tumor with oxygen and nutrients. To date, the role of PIGF in the development of a medulloblastoma has been unknown.
In collaboration with foreign scientists, Peter Carmeliet and his team studied the role of PIGF in various types of medulloblastoma in mice. The scientists demonstrated that PIGF is expressed in the majority of all medulloblastomas and that PIGF is essential for the survival of these tumors. The clinical importance of PIGF was also confirmed in patients with a medulloblastoma.
All these findings suggest that blocking PIGF could be of therapeutic importance. Studies in mice where PIGF was blocked with an antibody against PIGF resulted in delayed tumor growth, decreased metastasis to the spinal cord and a longer life expectancy.
The therapeutic potential of PIGF inhibitors in medulloblastoma requires further study. As PIGF only plays a role in the stimulation of blood vessel formation in diseases (such as cancer), the inhibition of this growth factor will have fewer harmful consequences than the current therapies. The current therapies block the most important angiogenic growth factor (VEGF), which also affects blood vessels in healthy tissue and causes side effects. In addition, due to their negative side effects (stopping growth) VEGF inhibitors cannot be used on children with cancers, whereas PIGF inhibitors can be used. VIB has licensed the rights for clinical development of anti-PIGF inhibitors to ThromboGenics N.V.